

Role of Vitamin-D in Reducing Need for Supplemental Oxygen Among COVID-19 Patients Anita Bajpai MD, Sarah Duan DO, Ashlee Erskine DO, Shehzein Khan DO, Raymond Kramer MD RUHS/UCR Family Medicine Program





Objectives

- Explore the role of Vitamin-D and its implications on clinical trajectory of Covid-19 patients
- Increase awareness among healthcare professionals so that appropriate preventive and treatment actions can be taken

Background

- Vitamin-D is well documented for its anti-inflammatory role as an adjuvant in regulation of cytokines and immune cells¹
- ➤ Research trials^{2,3} on impact of Vitamin-D on clinical outcomes for COVID-19 infection are still in nascent stages⁴

Study Aims – impact on need for oxygen ?




- Primary Aim:
- <u>Baseline Study</u>: Determine whether having healthy level of *baseline* Vitamin-D 25-OH (≥ 30ng/ml) helps improve the clinical trajectory of Covid-19 patients in terms of need for supplemental oxygen.
- Secondary Aim:
- After-the-fact study: Determine whether administering Vitamin-D after-the-fact for hospitalized Covid-19 patients reduces the need for supplemental oxygen.

Study Design



| | Item | | Overall Description | | Values | |
|------------------|--------------------|--|--------------------------------------|---|-------------|---|
| | Study Type | | Retrospective, Observational, Cohort | | | |
| | Location | | RUHS Medical Center, Moreno Valley | | Hospital | |
| | Duration | | March – December 2020 | | 10 months | |
| | Dependent Variable | | Peak O ₂ needed | | Real number | |
| | Variable Type | | Quantitative (positive real no.) | | > 0 L/min. | |
| Item | | | Baseline Study | After-the-fact Study | | У |
| pendent Variable | | Baseline Vitamin-D level | | Inpatient Administration of Vit-D | | |
| able Type Ca | | Categorical ≥ 30 ng/ml (yes/no) | | Categorical (yes/no) | | |
| usion Criteria | | All COVID-19 patients needing O_2 <u>AND</u> whose baseline Vit-D level is known ($N=182$ patients) | | All COVID-19 patients needing O_2 ($N=893$ patients) | | |

Analysis Flowcharts



Results/Findings

- ➤ <u>Baseline Study</u>: Mean values for *peak* oxygen flow rate for the group with healthy baseline level of Vitamin-D was 8.6 L/min vs. 12.6L/min for those with low or borderline levels, yielding a *p-value* of 0.07 (*p* < 0.10)
- After-the-fact Study: Mean values for *peak* oxygen flow rate for those not administered Vitamin-D was 12.5 L/min vs. 12.8L/min for those given Vitamin-D, yielding a *p-value* of 0.87 (*p* > 0.10)
- Figure 1. Given large sample sizes, the calculated statistical *power* for both our studies exceeded the customary norm of 80% or better ($\beta < 0.2$)



Conclusions

- ➤ We found that patients with healthy levels of Vitamin-D at baseline needed significantly lower levels of supplemental oxygen.
- This is consistent with published research⁵⁻⁸ promoting adequate baseline Vitamin-D among the population as a potential benefit in context of COVID-19.
- Interestingly, we found no statistically significant advantage for administering Vitamin-D in the hospital, *after-the fact*.
- This may be a case of "too little too late"
- Caveat it's possible that any delayed marginal benefits from after-the-fact Vitamin D may not have materialized promptly in the presence of significant inflammatory condition and larger influence of steroids and other EUA medicines.
- Published research^{5,6} indicates that since there is "low risk", providers should still consider inpatient Vitamin-D for potential benefits until more definitive findings are established.

References

- 1. Martineau AR, Forouhi NG. Vitamin D for COVID-19: A case to answer? Lancet Diabetes Endocrinol. 2020;8(9):735-736.
- 2. Murai IH, Fernandes AL, Sales LP, et al. Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe covid-19: A randomized clinical trial. *JAMA*. 2021;325(11):1053-1060.
- 3. Wang R, DeGruttola V, Lei Q, et al. The vitamin D for COVID-19 (VIVID) trial: A pragmatic cluster-randomized design. *Contemp Clin Trials*. 2021;100:106176.
- 4. Rubin R. Sorting out whether vitamin d deficiency raises covid-19 risk. JAMA. 2021;325(4):329-330.
- 5. Annweiler C, Cao Z, Sabatier J-M. Point of view: Should COVID-19 patients be supplemented with vitamin D? *Maturitas*. 2020;140:24-26.
- 6. Arboleda JF, Urcuqui-Inchima S. Vitamin D supplementation: a potential approach for coronavirus/covid-19 therapeutics? *Front Immunol*. 2020;11:1523.
- 7. Bergman P. The link between vitamin D and COVID-19: distinguishing facts from fiction. *J Intern Med*. 2021;289(1):131-133.
- 8. Mitchell F. Vitamin-D and COVID-19: do deficient risk a poorer outcome? *Lancet Diabetes Endocrinol*. 2020;8(7):570.